The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer program

Details

Serval ID
serval:BIB_CC7CF69A32AB
Type
Article: article from journal or magazin.
Collection
Publications
Title
The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer program
Journal
Fertility and Sterility
Author(s)
Olivennes  F., Fanchin  R., Bouchard  P., de Ziegler  D., Taieb  J., Selva  J., Frydman  R.
ISSN
0015-0282
Publication state
Published
Issued date
09/1994
Peer-reviewed
Oui
Volume
62
Number
3
Pages
468-76
Notes
Clinical Trial
Journal Article --- Old month value: Sep
Abstract
OBJECTIVE: To assess the ability of a GnRH antagonist (Cetrorelix, Asta Medica AG, Frankfurt, Germany) to prevent premature LH surges in an IVF-ET program using a simple protocol with one or two administrations. DESIGN: Controlled ovarian hyperstimulation was carried out in 17 women with three ampules a day of hMG, starting on day 2 of the menstrual cycle. A dose of 5 mg of Cetrorelix was administered when plasma E2 levels were between 150 and 200 pg/mL (conversion factor to Sl unit, 3.671) per follicle of > or = 14 mm. A second injection was performed 48 hours later if the triggering of ovulation was not decided in the meantime. RESULTS: Six patients received one injection and 11 patients received two administrations. Plasma LH levels showed a marked decrease and remained low after the administration of the GnRH antagonist. In six patients, the first administration of Cetrorelix was performed when a significant rise in LH plasma level was present. Even in these patients the GnRH antagonist was able to prevent an LH surge. The tolerance of the product was good. Six clinical pregnancies were obtained, of which four are ongoing (25% per ET). Two ongoing pregnancies were obtained after the transfer of a frozen-thawed embryo (35.3% per retrieval). CONCLUSIONS: The GnRH antagonist Cetrorelix in a simple, unique or dual administration, protocol was able to prevent premature LH surge in all of the 17 patients studied. If these results are confirmed by larger, randomized studies, the good tolerance and efficacy that we observed suggest a bright future for this product is assisted reproductive technologies.
Keywords
Adult *Embryo Transfer Estradiol/blood Female *Fertilization in Vitro Follicle Stimulating Hormone/blood Gonadotropin-Releasing Hormone/administration & dosage/*analogs & derivatives/antagonists & inhibitors/therapeutic use Humans Injections, Subcutaneous Luteinizing Hormone/blood Pregnancy Progesterone/blood
Pubmed
Web of science
Create date
28/02/2008 11:37
Last modification date
20/08/2019 15:47
Usage data